Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$26.20

-0.03 (-0.11%)

04:55
10/06/17
10/06
04:55
10/06/17
04:55

Aimmune management to meet with JMP Securities

Meeting to be held in Dallas on October 6 hosted by JMP Securities.

  • 06

    Oct

  • 17

    Oct

  • 18

    Oct

  • 06

    Nov

AIMT Aimmune
$26.20

-0.03 (-0.11%)

02/17/17
PIPR
02/17/17
NO CHANGE
Target $40
PIPR
Overweight
Piper sees Aimmune trial changes as reducing clinical risk
Piper Jaffray analyst Charles Duncan believes the Phase III change announced yesterday by Aimmune Therapeutics (AIMT) reduces clinical risk for the trial read-out, while still addressing a broad group of children and teens more broadly relative to Aimmune's "mindshare competitor" DBV Technologies (DBVT). The PALISADE Phase III primary analysis and initial BLA application will now include ages 4-17, but exclude adult patients, Duncan tells investors in a research note. Following the news, the analyst still believes Aimmune's AR101 will be approved and used in some of adult patients, but points out another trial may be required. He pushed his first AR101 sales estimate in adults back by two years to 2021 in the U.S. market and 2020 to 2022 in the E.U. market. Duncan keeps an Overweight rating on Aimmune with a $40 price target.
03/22/17
PIPR
03/22/17
NO CHANGE
Target $38
PIPR
Overweight
Piper sees Aimmune as having regulatory advantage over DBV
After hosting investor meetings with management, Piper Jaffray analyst Charles Duncan keeps an Overweight rating on Aimmune (AIMT) with a $38 price target. While regulatory visibility will increase in the next 12 months, investors today should focus on response rates for the single highest tolerated dose, or how much peanut can an allergic person tolerate in a single exposure, Duncan tells investors in a research note. The analyst sees Aimmune's AR101 as having generated "uniquely impressive results" on the two key efficacy measures relative to DBV Technologies (DBVT), including both response rates and size of highest tolerated dose. He believes investors may be overlooking catalysts for Aimmune, including up-dosing progress from the PALISADE trial prior to Phase III results around year-end.
09/12/17
JEFF
09/12/17
NO CHANGE
Target $51
JEFF
Buy
Jefferies allergist poll shows 'meaningful upside' to DBV sales estimates
Jefferies analyst Eun Yang says her firm's poll of 33 U.S. allergists indicates "meaningful upside" to her Viaskin Peanut sales estimates in the $3.5B U.S. pediatric peanut allergy market should DBV Technologies (DBVT) win approval. The poll indicates a preference for Viaskin Peanut over Aimmune Therapeutics' (AIMT) AR101 in kids with peanut allergy given its safety profile and convenience, Yang tells investors in a research note. The analyst sees a "high likelihood" of Phase 3 success for Viaskin Peanut, which DBV is expected to announce in October. On positive data, the stock could rally up to 50% from current levels, the analyst contends. She keeps a Buy rating on DBV Technologies.
10/02/17
JMPS
10/02/17
NO CHANGE
JMPS
Outperform
Parents excited about peanut allergy immunotherapy, says JMP Securities
After surveying over 60 parents with peanut allergic children, JMP Securities analyst Liisa Bayko said she was "surprised" that 85% of respondents indicated a willingness to adopt an immunotherapy to treat the allergy. While the survey group may represent a more engaged and proactive one than the larger population, Bayko said even 30% adoption would be significant as the peanut allergy market is "enormous". The analyst, who added the survey pointed to a place for both oral and epicutaneous approaches, keeps Outperform ratings on both DBV Technologies (DBVT) and Aimmune (AIMT).

TODAY'S FREE FLY STORIES

SGMS

Scientific Games

$42.85

0.1 (0.23%)

08:47
10/19/17
10/19
08:47
10/19/17
08:47
Hot Stocks
Scientific Games' casino management system selected by Snoqualmie Casino »

Scientific Games will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

AAOI

Applied Optoelectronics

$42.29

-1.45 (-3.32%)

, XME

SPDR S&P Metals & Mining

$32.73

0.15 (0.46%)

08:45
10/19/17
10/19
08:45
10/19/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

AAOI

Applied Optoelectronics

$42.29

-1.45 (-3.32%)

XME

SPDR S&P Metals & Mining

$32.73

0.15 (0.46%)

CBI

CB&I

$15.85

-0.19 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 16

    Nov

08:45
10/19/17
10/19
08:45
10/19/17
08:45
General news
Treasury Action: yields stabilized above lows »

Treasury Action: yields…

HRL

Hormel Foods

$31.34

-0.17 (-0.54%)

08:44
10/19/17
10/19
08:44
10/19/17
08:44
Recommendations
Hormel Foods analyst commentary  »

Hormel Foods price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$159.76

-0.71 (-0.44%)

, HNHPF

Hon Hai Precision

$7.49

0.412 (5.82%)

08:44
10/19/17
10/19
08:44
10/19/17
08:44
Periodicals
Apple, suppliers fall after report of reduced iPhone 8 orders, Bloomberg says »

Shares of Apple (AAPL)…

AAPL

Apple

$159.76

-0.71 (-0.44%)

HNHPF

Hon Hai Precision

$7.49

0.412 (5.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

GALT

Galectin Therapeutics

$2.51

0.22 (9.61%)

08:44
10/19/17
10/19
08:44
10/19/17
08:44
Initiation
Galectin Therapeutics initiated  »

Galectin Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDGL

Madrigal Pharmaceuticals

$47.52

0.51 (1.08%)

08:42
10/19/17
10/19
08:42
10/19/17
08:42
Initiation
Madrigal Pharmaceuticals initiated  »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

RMBL

RumbleON

$9.30

0.3 (3.33%)

08:42
10/19/17
10/19
08:42
10/19/17
08:42
Syndicate
RumbleON 2.91M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

XPO

XPO Logistics

$64.76

0.12 (0.19%)

08:40
10/19/17
10/19
08:40
10/19/17
08:40
Hot Stocks
Department of Defense boosts XPO contract by $139.5M to $2.32B »

The Department of Defense…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

GEMP

Gemphire Therapeutics

$9.54

-0.08 (-0.83%)

08:40
10/19/17
10/19
08:40
10/19/17
08:40
Initiation
Gemphire Therapeutics initiated  »

Gemphire Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$37.97

0.48 (1.28%)

08:39
10/19/17
10/19
08:39
10/19/17
08:39
Recommendations
eBay analyst commentary  »

eBay progress…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:39
10/19/17
10/19
08:39
10/19/17
08:39
Hot Stocks
Genuine Parts announces two industrial and automotive acquisitions »

Genuine Parts announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

BANR

Banner Corp.

$61.29

0.54 (0.89%)

, PUB

People's Utah Bancorp

$32.85

0.2 (0.61%)

08:38
10/19/17
10/19
08:38
10/19/17
08:38
Conference/Events
People's Utah Bancorp to hold a conference call »

Management discusses…

BANR

Banner Corp.

$61.29

0.54 (0.89%)

PUB

People's Utah Bancorp

$32.85

0.2 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 26

    Oct

  • 09

    Nov

MTG

MGIC Investment

$13.54

0.43 (3.28%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Recommendations
MGIC Investment analyst commentary  »

MGIC Investment price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$153.00

2.62 (1.74%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 06

    Nov

IFMK

iFresh

$12.15

-0.1 (-0.82%)

08:37
10/19/17
10/19
08:37
10/19/17
08:37
Hot Stocks
iFresh announces exclusive agreement with Dragon Seeds »

iFresh announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$7.00

-0.05 (-0.71%)

08:36
10/19/17
10/19
08:36
10/19/17
08:36
Technical Analysis
Technical View: Corbus Pharmaceuticals surges on anabasum Phase 2 results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$12.33

0.01 (0.08%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Hot Stocks
Celestica appoints Mandeep Chawla as CFO »

Celestica announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Hot Stocks
Genuine Parts CEO: Q3 'presented us with both opportunities and challenges' »

Paul Donahue, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Recommendations
American Express analyst commentary  »

American Express guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 08

    Nov

AXP

American Express

$92.08

0.39 (0.43%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Recommendations
American Express analyst commentary  »

American Express price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 08

    Nov

AGEN

Agenus

$4.71

0.04 (0.86%)

, ADRO

Aduro Biotech

$9.55

-0.1 (-1.04%)

08:35
10/19/17
10/19
08:35
10/19/17
08:35
Conference/Events
William Blair biotech analyst holds an analyst/industry conference call Aduro Biotech »

Biotech Analyst Phipps,…

AGEN

Agenus

$4.71

0.04 (0.86%)

ADRO

Aduro Biotech

$9.55

-0.1 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 24

    Oct

ARNA

Arena Pharmaceuticals

$27.56

0.71 (2.64%)

08:34
10/19/17
10/19
08:34
10/19/17
08:34
Hot Stocks
Arena Pharmaceuticals reports Phase 2 results of ralinepag in hypertension »

Arena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VCYT

Veracyte

$9.19

0.29 (3.26%)

08:33
10/19/17
10/19
08:33
10/19/17
08:33
Hot Stocks
Veracyte to present data on Percepta Bronchial Genomic Classifier at CHEST 2017 »

Veracyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPC

Genuine Parts

$98.04

1.18 (1.22%)

08:32
10/19/17
10/19
08:32
10/19/17
08:32
Earnings
Genuine Parts cuts FY17 adjusted EPS view to $4.55-$4.60 from $4.70-$4.75 »

FY17 consensus $4.73.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.